Related Experiment Videos
Controlled activity mite vaccines for 'barn allergy'
Abstract:
Three species of mites, Tyrophagus longior, Glyciphagus destructor, and Acarus farris have been isolated from the dust of barns of farms in Orkney. The mites were cultured in amount sufficient for the production of bulk extracts. These were then tested by skin prick in a population of 30 inhabitants of Orkney and potency was assigned in units of biologic activity. The concentrations of the bulk extracts from the different species were adjusted to the same biologic potency and then used to make delayed-release vaccines for injection therapy and aqueous solutions for provocation tests and therapy by the nasal route. The vaccines were then administered by injection to nine subjects at weekly intervals over a period of 2 months. Assessment by questionnaire suggested that there was a significant improvement in the symptoms of eight of the nine subjects. A course of nasal therapy with the aqueous solutions produced no improvement in four out of five subjects.
Insights
Mite immunotherapy using delayed-release vaccines showed significant symptom improvement in eight of nine subjects. Nasal therapy with mite extracts did not yield similar positive outcomes in this study.
Area of Science:
- Allergen immunotherapy
- Clinical immunology
- Agricultural entomology
Background:
- Mites are common allergens found in agricultural environments.
- Dust mites, including Tyrophagus longior, Glyciphagus destructor, and Acarus farris, are prevalent in Orkney farm barns.
- Standardized allergen extracts are crucial for effective immunotherapy.
Purpose of the Study:
- To develop and evaluate mite allergen extracts for immunotherapy.
- To assess the efficacy of delayed-release injectable vaccines versus nasal therapy.
- To determine the clinical benefit of mite immunotherapy in a local population.
Main Methods:
- Isolation and culturing of three mite species: Tyrophagus longior, Glyciphagus destructor, and Acarus farris.
- Production of bulk mite extracts and standardization of biologic potency.
- Administration of delayed-release vaccines via injection to nine subjects over 2 months.
- Nasal provocation tests and therapy with aqueous mite solutions in five subjects.
Main Results:
- Injection therapy with delayed-release mite vaccines resulted in significant symptom improvement in 8 out of 9 subjects.
- Nasal therapy with aqueous mite solutions showed no improvement in 4 out of 5 subjects.
- Skin prick testing was used to assess initial allergen potency.
Conclusions:
- Delayed-release injectable mite vaccines appear to be an effective therapeutic option for mite-sensitive individuals.
- Nasal administration of mite allergen solutions showed limited efficacy in this study.
- Further research is warranted to optimize mite immunotherapy protocols.